Eco Animal Health (LSE:EAH) reported strong trading for the year ending 31 March 2026, building on momentum from a solid first half. The company now expects full-year revenue to increase by roughly 8% year on year, coming in slightly ahead of market expectations. Sales growth was particularly strong in North America and Latin America, where higher demand offset the impact of currency movements and tariff pressures.
The group also anticipates improved gross margins for the year, driven by stronger product pricing and a reduction in the cost of goods sold. As a result, adjusted EBITDA is expected to rise significantly compared with the previous year and to exceed analyst consensus forecasts. The upgraded outlook highlights the veterinary pharmaceuticals company’s improving profitability ahead of the release of its audited annual results, scheduled for early July.
Eco Animal Health’s outlook reflects strong technical momentum and supportive corporate developments, suggesting confidence in its growth trajectory. However, the shares carry a relatively high valuation and the company’s historical financial performance has been somewhat uneven, which introduces potential risks if growth expectations are not fully delivered.
More about Eco Animal Health
Eco Animal Health Group is a UK-based global animal health company specialising in the development and marketing of branded veterinary pharmaceuticals. Its product portfolio focuses primarily on antibiotics and vaccines for pigs and poultry.
The company’s flagship product, Aivlosin, is a patented treatment used to combat respiratory and intestinal diseases in pigs and poultry. Eco Animal Health markets its products in more than 70 countries worldwide, positioning itself as a specialist provider of solutions for livestock health and productivity.
Leave a Reply